A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy

Charles W. Taylor, Manuel R. Modiano, Mark E. Woodson, Stephen G. Marcus, David S Alberts, Evan M Hersh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We conducted a phase I trial of fluorouracil (5-FU), leucovorin, (LCV), and recombinant interferon-α-2b (rIFNα-2b). The doses of each of the three agents were escalated sequentially. 5-FU and LCV were administered by IV bolus, weekly for 6 weeks and rIFN-α-2b was administered by subcutaneous injection, three times weekly for 6 weeks. Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated. Partial remissions were observed in three patients (10%) with previously untreated colon cancer, colon cancer refractory to 5-FU plus LCV and previously untreated pancreatic cancer, respectively. An additional three patients with pancreatic, prostate, and rectal cancer had a 50% reduction in tumor markers but no change in objective tumor measurements. The toxicity of this regimen was tolerable. The most common toxicities were diarrhea, fatigue, flu-like symptoms, nausea/vomiting, and mucositis. However, no fatal or life-threatening toxicities were observed. We conclude that the combination of 5-FU, LCV, and rIFN-α-2b can be safely administered and recommend further evaluation of this regimen in patients with tumors of gastrointestinal origin using doses of 5-FU 600 mg/m2, LCV 500 mg/m2, and rIFN-α-2b 10 × 106 U.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalSeminars in Oncology
Volume19
Issue number2 SUPPL. 3
StatePublished - 1992

Fingerprint

Leucovorin
Fluorouracil
Interferons
Colonic Neoplasms
Pancreatic Neoplasms
Neoplasms
Mucositis
Subcutaneous Injections
Rectal Neoplasms
Tumor Biomarkers
Nausea
Vomiting
Fatigue
Diarrhea
Prostatic Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy. / Taylor, Charles W.; Modiano, Manuel R.; Woodson, Mark E.; Marcus, Stephen G.; Alberts, David S; Hersh, Evan M.

In: Seminars in Oncology, Vol. 19, No. 2 SUPPL. 3, 1992, p. 185-190.

Research output: Contribution to journalArticle

Taylor, Charles W. ; Modiano, Manuel R. ; Woodson, Mark E. ; Marcus, Stephen G. ; Alberts, David S ; Hersh, Evan M. / A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy. In: Seminars in Oncology. 1992 ; Vol. 19, No. 2 SUPPL. 3. pp. 185-190.
@article{a1e0280f093c4f218f37615b1bf6b358,
title = "A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy",
abstract = "We conducted a phase I trial of fluorouracil (5-FU), leucovorin, (LCV), and recombinant interferon-α-2b (rIFNα-2b). The doses of each of the three agents were escalated sequentially. 5-FU and LCV were administered by IV bolus, weekly for 6 weeks and rIFN-α-2b was administered by subcutaneous injection, three times weekly for 6 weeks. Twenty-nine patients with advanced cancer (75{\%} colon or pancreatic cancer) were treated. Partial remissions were observed in three patients (10{\%}) with previously untreated colon cancer, colon cancer refractory to 5-FU plus LCV and previously untreated pancreatic cancer, respectively. An additional three patients with pancreatic, prostate, and rectal cancer had a 50{\%} reduction in tumor markers but no change in objective tumor measurements. The toxicity of this regimen was tolerable. The most common toxicities were diarrhea, fatigue, flu-like symptoms, nausea/vomiting, and mucositis. However, no fatal or life-threatening toxicities were observed. We conclude that the combination of 5-FU, LCV, and rIFN-α-2b can be safely administered and recommend further evaluation of this regimen in patients with tumors of gastrointestinal origin using doses of 5-FU 600 mg/m2, LCV 500 mg/m2, and rIFN-α-2b 10 × 106 U.",
author = "Taylor, {Charles W.} and Modiano, {Manuel R.} and Woodson, {Mark E.} and Marcus, {Stephen G.} and Alberts, {David S} and Hersh, {Evan M}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "185--190",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 3",

}

TY - JOUR

T1 - A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy

AU - Taylor, Charles W.

AU - Modiano, Manuel R.

AU - Woodson, Mark E.

AU - Marcus, Stephen G.

AU - Alberts, David S

AU - Hersh, Evan M

PY - 1992

Y1 - 1992

N2 - We conducted a phase I trial of fluorouracil (5-FU), leucovorin, (LCV), and recombinant interferon-α-2b (rIFNα-2b). The doses of each of the three agents were escalated sequentially. 5-FU and LCV were administered by IV bolus, weekly for 6 weeks and rIFN-α-2b was administered by subcutaneous injection, three times weekly for 6 weeks. Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated. Partial remissions were observed in three patients (10%) with previously untreated colon cancer, colon cancer refractory to 5-FU plus LCV and previously untreated pancreatic cancer, respectively. An additional three patients with pancreatic, prostate, and rectal cancer had a 50% reduction in tumor markers but no change in objective tumor measurements. The toxicity of this regimen was tolerable. The most common toxicities were diarrhea, fatigue, flu-like symptoms, nausea/vomiting, and mucositis. However, no fatal or life-threatening toxicities were observed. We conclude that the combination of 5-FU, LCV, and rIFN-α-2b can be safely administered and recommend further evaluation of this regimen in patients with tumors of gastrointestinal origin using doses of 5-FU 600 mg/m2, LCV 500 mg/m2, and rIFN-α-2b 10 × 106 U.

AB - We conducted a phase I trial of fluorouracil (5-FU), leucovorin, (LCV), and recombinant interferon-α-2b (rIFNα-2b). The doses of each of the three agents were escalated sequentially. 5-FU and LCV were administered by IV bolus, weekly for 6 weeks and rIFN-α-2b was administered by subcutaneous injection, three times weekly for 6 weeks. Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated. Partial remissions were observed in three patients (10%) with previously untreated colon cancer, colon cancer refractory to 5-FU plus LCV and previously untreated pancreatic cancer, respectively. An additional three patients with pancreatic, prostate, and rectal cancer had a 50% reduction in tumor markers but no change in objective tumor measurements. The toxicity of this regimen was tolerable. The most common toxicities were diarrhea, fatigue, flu-like symptoms, nausea/vomiting, and mucositis. However, no fatal or life-threatening toxicities were observed. We conclude that the combination of 5-FU, LCV, and rIFN-α-2b can be safely administered and recommend further evaluation of this regimen in patients with tumors of gastrointestinal origin using doses of 5-FU 600 mg/m2, LCV 500 mg/m2, and rIFN-α-2b 10 × 106 U.

UR - http://www.scopus.com/inward/record.url?scp=0026600816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026600816&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 185

EP - 190

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 3

ER -